REFERENCES

1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618-731.

2. van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58:2511-9.

3. Zhang Y, Bonnet S, Provencher S, et al. Critical contribution of cardiac myofibroblasts in right ventricular failure and the role of UCP2 SNPs in the predisposition to RV decompensation in pulmonary arterial hypertension. Circulation. 2026;153:1494-515.

4. Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2021;117:1450-88.

5. Aujla PK, Kassiri Z. Diverse origins and activation of fibroblasts in cardiac fibrosis. Cell Signal. 2021;78:109869.

6. McNair BD, Shorthill SK, Bruns DR. More than just a small left ventricle: the right ventricular fibroblast and ECM in health and disease. Am J Physiol Heart Circ Physiol. 2023;325:H385-97.

7. Frangogiannis NG. Fibroblasts and the extracellular matrix in right ventricular disease. Cardiovasc Res. 2017;113:1453-64.

8. Humeres C, Frangogiannis NG. Fibroblasts in the infarcted, remodeling, and failing heart. JACC Basic Transl Sci. 2019;4:449-67.

9. López B, Ravassa S, Moreno MU, et al. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nat Rev Cardiol. 2021;18:479-98.

10. Dromparis P, Paulin R, Sutendra G, Qi AC, Bonnet S, Michelakis ED. Uncoupling protein 2 deficiency mimics the effects of hypoxia and endoplasmic reticulum stress on mitochondria and triggers pseudohypoxic pulmonary vascular remodeling and pulmonary hypertension. Circ Res. 2013;113:126-36.

11. Hoque MM, Gbadegoye JO, Hassan FO, Raafat A, Lebeche D. Cardiac fibrogenesis: an immuno-metabolic perspective. Front Physiol. 2024;15:1336551.

12. Cadosch N, Gil-Cruz C, Perez-Shibayama C, Ludewig B. Cardiac fibroblastic niches in homeostasis and inflammation. Circ Res. 2024;134:1703-17.

13. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010;122:920-7.

14. Michelakis ED, Gurtu V, Webster L, et al. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Sci Transl Med. 2017;9:eaao4583.

15. Prisco SZ, Thenappan T, Prins KW. Treatment targets for right ventricular dysfunction in pulmonary arterial hypertension. JACC Basic Transl Sci. 2020;5:1244-60.

16. Dayer N, Ltaief Z, Liaudet L, Lechartier B, Aubert JD, Yerly P. Pressure overload and right ventricular failure: from pathophysiology to treatment. J Clin Med. 2023;12:4722.